These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 32153201)

  • 1. Ruxolitinib for the treatment of graft-versus-host disease.
    Ali H; Salhotra A; Modi B; Nakamura R
    Expert Rev Clin Immunol; 2020 Apr; 16(4):347-359. PubMed ID: 32153201
    [No Abstract]   [Full Text] [Related]  

  • 2. Ruxolitinib for the treatment of patients with steroid-refractory GVHD: an introduction to the REACH  trials.
    Jagasia M; Zeiser R; Arbushites M; Delaite P; Gadbaw B; Bubnoff NV
    Immunotherapy; 2018 Apr; 10(5):391-402. PubMed ID: 29316837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628).
    von Bubnoff N; Ihorst G; Grishina O; Röthling N; Bertz H; Duyster J; Finke J; Zeiser R
    BMC Cancer; 2018 Nov; 18(1):1132. PubMed ID: 30453910
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ruxolitinib: a potential treatment for corticosteroid refractory acute graft-versus-host disease.
    Abedin SM; Hamadani M
    Expert Opin Investig Drugs; 2020 May; 29(5):423-427. PubMed ID: 32293938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease.
    Zeiser R; von Bubnoff N; Butler J; Mohty M; Niederwieser D; Or R; Szer J; Wagner EM; Zuckerman T; Mahuzier B; Xu J; Wilke C; Gandhi KK; Socié G;
    N Engl J Med; 2020 May; 382(19):1800-1810. PubMed ID: 32320566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
    Zeiser R; Polverelli N; Ram R; Hashmi SK; Chakraverty R; Middeke JM; Musso M; Giebel S; Uzay A; Langmuir P; Hollaender N; Gowda M; Stefanelli T; Lee SJ; Teshima T; Locatelli F;
    N Engl J Med; 2021 Jul; 385(3):228-238. PubMed ID: 34260836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ruxolitinib in steroid refractory graft-vs.-host disease: a case report.
    Maffini E; Giaccone L; Festuccia M; Brunello L; Buondonno I; Ferrero D; Boccadoro M; Dellacasa C; Busca A; Novero D; Bruno B
    J Hematol Oncol; 2016 Aug; 9(1):67. PubMed ID: 27502249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy, Toxicity, and Infectious Complications in Ruxolitinib-Treated Patients with Corticosteroid-Refractory Graft-versus-Host Disease after Hematopoietic Cell Transplantation.
    Abedin S; McKenna E; Chhabra S; Pasquini M; Shah NN; Jerkins J; Baim A; Runaas L; Longo W; Drobyski W; Hari PN; Hamadani M
    Biol Blood Marrow Transplant; 2019 Aug; 25(8):1689-1694. PubMed ID: 30965140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficiency and Toxicity of Ruxolitinib as a Salvage Treatment for Steroid-Refractory Chronic Graft-Versus-Host Disease.
    Wang D; Liu Y; Lai X; Chen J; Cheng Q; Ma X; Lin Z; Wu D; Xu Y
    Front Immunol; 2021; 12():673636. PubMed ID: 34276662
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacologic Inhibition of JAK1/JAK2 Signaling Reduces Experimental Murine Acute GVHD While Preserving GVT Effects.
    Carniti C; Gimondi S; Vendramin A; Recordati C; Confalonieri D; Bermema A; Corradini P; Mariotti J
    Clin Cancer Res; 2015 Aug; 21(16):3740-9. PubMed ID: 25977345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel JAK Inhibitors to Reduce Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation in a Preclinical Mouse Model.
    Kim S; Ruminski P; Singh M; Staser K; Ashami K; Ritchey J; Lim S; DiPersio JF; Choi J
    Molecules; 2024 Apr; 29(8):. PubMed ID: 38675621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Ruxolitinib for treatment of GvHD in patients with myelofibrosis].
    Mori Y
    Rinsho Ketsueki; 2019; 60(8):953-959. PubMed ID: 31484895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ruxolitinib, a JAK1/JAK2 selective inhibitor, ameliorates acute and chronic steroid-refractory GvHD mouse models.
    Huarte E; Peel M; Juvekar A; Dubé P; Sarah S; Stephens L; Stewart B; Long B; Czerniak P; Oliver J; Smith P
    Immunotherapy; 2021 Aug; 13(12):977-987. PubMed ID: 34184542
    [No Abstract]   [Full Text] [Related]  

  • 14. Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.
    Zeiser R; Burchert A; Lengerke C; Verbeek M; Maas-Bauer K; Metzelder SK; Spoerl S; Ditschkowski M; Ecsedi M; Sockel K; Ayuk F; Ajib S; de Fontbrune FS; Na IK; Penter L; Holtick U; Wolf D; Schuler E; Meyer E; Apostolova P; Bertz H; Marks R; Lübbert M; Wäsch R; Scheid C; Stölzel F; Ordemann R; Bug G; Kobbe G; Negrin R; Brune M; Spyridonidis A; Schmitt-Gräff A; van der Velden W; Huls G; Mielke S; Grigoleit GU; Kuball J; Flynn R; Ihorst G; Du J; Blazar BR; Arnold R; Kröger N; Passweg J; Halter J; Socié G; Beelen D; Peschel C; Neubauer A; Finke J; Duyster J; von Bubnoff N
    Leukemia; 2015 Oct; 29(10):2062-8. PubMed ID: 26228813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ruxolitinib in the management of steroid-resistant/-dependent acute and chronic graft-versus-host disease: results of routine practice in an academic centre.
    Leung GMK; Sim JPY; Hwang YY; Chan TSY; Lie AKW; Tse E; Kwong YL
    Ann Hematol; 2022 Jan; 101(1):155-163. PubMed ID: 34767056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ruxolitinib for steroid-refractory graft versus host disease in pediatric HSCT: high response rate and manageable toxicity.
    Mozo Y; Bueno D; Sisinni L; Fernández-Arroyo A; Rosich B; Martínez AP; Benítez-Carabante MI; Alonso L; Uría ML; Heredia CD; Mestre-Duran C; Pascual CFB; Torres J; Losantos I; Escudero A; Ruz-Caracuel B
    Pediatr Hematol Oncol; 2021 May; 38(4):331-345. PubMed ID: 33661711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical evaluation of JAK1/2 inhibition by ruxolitinib in a murine model of chronic graft-versus-host disease.
    Ryu DB; Lim JY; Kim TW; Shin S; Lee SE; Park G; Min CK
    Exp Hematol; 2021 Jun; 98():36-46.e2. PubMed ID: 33811972
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib, an oral JAK1 and JAK2 inhibitor, in myelofibrosis.
    Vaddi K; Sarlis NJ; Gupta V
    Expert Opin Pharmacother; 2012 Nov; 13(16):2397-407. PubMed ID: 23051187
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for the treatment of acute graft-versus-host disease: a retrospective analysis.
    Denk A; Edinger M; Weber D; Holler E; Fante M; Meedt E; Gunes S; Poeck H; Mittermaier C; Herr W; Wolff D
    Ann Hematol; 2024 Aug; 103(8):3071-3081. PubMed ID: 38916740
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.